Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. We in-licensing the global development and commercialization rights to three drug candidates -- PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Puma was founded in September 2010 as a private company and incorporated in Delaware.
On October 4, 2011, Puma completed a reverse merger with Innovative Acquisitions Corp., a publicly reporting “shell” company with no specific business plan or purpose. As a result of the merger, Puma became a wholly owned subsidiary of Innovative Acquisitions. The merged company changed its name to Puma Biotechnology and adopted Puma’s business plan. The company’s common stock began trading on April 20, 2012.
Puma Biotechnology moved its common stock listing to the Nasdaq Stock Market on January 3, 2017, and trades under the symbol "PBYI." From October 19, 2012, through December 30, 2016, PBYI was listed on the New York Stock Exchange. Previously, PBYI was quoted on the OTC Bulletin Board and OTCQB Market.
As of April 18, 2022, there were 44,973,141 shares of Puma Biotechnology common stock outstanding.
The CUSIP number for Puma Biotechnology common stock is 74587V107.
No.
EQ Shareowner Services SM.
EQ Shareowner Services SM P.O. Box 64854 St Paul, MN 55164 Phone: (1) 800-468-9716 Website: www.shareowneronline.com
KPMG LLP
December 31.
The 2022 annual meeting of stockholders will be held at 1:00 p.m. PDT on June 14, 2022, at Puma's headquarters in Los Angeles.
Puma’s headquarters are located at 10880 Wilshire Blvd., Suite 2150, Los Angeles, CA 90024.
Puma’s financial statements and other reports filed with the SEC are available on the SEC Filings page of our website at https://investor.pumabiotechnology.com/sec-filings/financials.
Please contact Mariann Ohanesian, Senior Director, Investor Relations:Phone: (1) 424-248-6500, Ext. 2011 Email: ir@pumabiotechnology.com